US FDA grants pamrevlumab Rare Pediatric Disease Designation for the treatment of Duchenne Muscular Dystrophy

Pamrevlumab is a first-in-class antibody that inhibits the activity of connective tissue growth factor. It is in Phase 3 clinical development for the treatment of locally advanced unresectable pancreatic cancer, Duchenne muscular dystrophy, and idiopathic pulmonary fibrosis.

Source:

Biospace Inc.